PRESS RELEASE

Retrophin Expands Management Team with Appointment of Steven R. Eby, R.Ph as Vice President, Global Strategy and Program Management

NEW YORK--(BUSINESS WIRE)-- Retrophin, Inc. (RTRX), a pharmaceutical company focused on the discovery and development of drugs for the treatment of catastrophic diseases that are debilitating and often life-threatening, today announced that Steven R. Eby, R.Ph has begun serving as a consultant to the Company and will be joining Retrophin as Vice President, Global Strategy and Program Management, responsible for the oversight of Retrophin's development programs and global strategy. Mr. Eby reports directly to Dr. Horacio Plotkin, Chief Medical Officer.

Commenting on today's news, Dr. Plotkin noted, "We are very pleased to welcome Steven to the Retrophin management team. This is an exciting and critical time for the Company, as we remain laser focused on the initiation and implementation of our FONT-3 clinical trial for RE-021 for the treatment of patients with Focal Segmental Glomerulosclerosis (FSGS), and as we concurrently pursue the development of RE-024 for Pantothenate kinase-associated neurodegeneration (PKAN), a rare and life-threatening neurological disorder. We look forward to leveraging Steven's more than two decades of proven experience in the pharmaceutical and biotechnology industries to help guide us in the successful development of our growing product pipeline, as well as in shaping our global strategy as we seek to maximize the opportunities ahead of us."

Prior to consulting for Retrophin, Mr. Eby held various positions of increasing responsibility with Genzyme Corporation for 15 years until its acquisition by Sanofi-Aventis. Most recently, Mr. Eby served as Vice President, Clinical Development & Medical Affairs (CMDA) Forecasting & Planning. In that role, Mr. Eby was responsible for global planning, forecasting and resource planning for the Development Organization, with a budget approximating $320 million. During his tenure at Genzyme, Mr. Eby also served as Senior Director, R&D Planning Operations, Director, Program Management, and Associate Director, Program Management. Prior to Genzyme, Mr. Eby held various roles in the Pharmacovigilance, Medical Information and Regulatory divisions of Serono Laboratories, Inc. and Wyeth-Ayerst Laboratories, Inc.

Mr. Eby earned his MBA from Babson College-FW Olin Graduate School of Business. Additionally, he holds a Bachelor of Science degree in Biology from Eastern Mennonite University as well as a Bachelor of Science degree in Pharmacy from the University of the Sciences in Philadelphia-Philadelphia College of Pharmacy. Mr. Eby is a Registered Pharmacist in the Commonwealth of Massachusetts.

About Retrophin

Retrophin is a pharmaceutical company focused on the discovery and development of drugs for the treatment of debilitating and often life-threatening diseases for which there are currently no viable patient options. The Company is currently focused on several catastrophic diseases affecting children, including Focal Segmental Glomerulosclerosis (FSGS), Pantothenate Kinase-Associated Neurodegeneration (PKAN), Duchenne Muscular Dystrophy and others. Retrophin's lead compound, RE-021, is scheduled to begin enrollment in a potentially pivotal Phase 2 clinical trial for FSGS during 2013. For additional information, please visit www.retrophin.com.

Forward-Looking Statements

This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995, regarding the research, development and commercialization of pharmaceutical products. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. No forward-looking statement can be guaranteed. Forward-looking statements in the press release should be evaluated together with the many uncertainties that affect the Company's business. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.